Boston Scientific Corporation (BSX)
After hours:
| Previous close | 55.03 |
| Open | 54.87 |
| Bid | 54.99 x 1100 |
| Ask | 54.93 x 800 |
| Day's range | 54.52 - 55.05 |
| 52-week range | 44.35 - 56.22 |
| Volume | |
| Avg. volume | 7,936,195 |
| Market cap | 80.501B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | 67.01 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Boston Scientific Closes Acquisition of Relievant Medsystems, Inc.
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only U.S. Food and Drug Administration-cleared Intracept® Intraosseous Nerve Ablation System, a therapy to treat vertebrogenic pain that is a form of chronic low back pain. The Intracept system, a basivertebral nerve ablation therapy, will be an addition to the Boston Scientific chronic pain portfolio that includes spinal cord stimulation, radiofrequency
- PR Newswire
Boston Scientific to Participate in Stifel's 2023 Healthcare Conference
Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2023 Healthcare Conference on Tuesday, November 14, 2023.
- PR Newswire
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2023
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational1 basis and 10.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $505 million or $0.34 per share (EPS), compared to $174 million or $0.12 per share a year ago, and achieved adjusted3 EPS of $0.50 for
